Crescent Biopharma, Inc. (CBIO) stock
CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 10/30
$14.15−0.22 (-1.53%)
Close on Nov 13, 2026Market cap $525.59MP/E –Yield –
Crescent Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
Crescent Biopharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $166.63M, up 284.9% year over year. For fiscal 2025 it was $138.09M, up 868.4% from the year before. Over ten years it grew 18.6% a year on average. The highest annual figure on record is $138.09M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $138.09M | +868.4% |
| FY2024 | Dec 31, 2024 | $14.26M | -29.0% |
| FY2023 | Dec 31, 2023 | $20.07M | -29.3% |
| FY2022 | Dec 31, 2022 | $28.39M | -40.2% |
| FY2021 | Dec 31, 2021 | $47.49M | +5.7% |
| FY2020 | Dec 31, 2020 | $44.93M | -4.5% |
| FY2019 | Dec 31, 2019 | $47.03M | +17.3% |
| FY2018 | Dec 31, 2018 | $40.09M | +66.4% |
| FY2017 | Dec 31, 2017 | $24.10M | +3.5% |
| FY2016 | Dec 31, 2016 | $23.28M | -7.1% |
| FY2015 | Dec 31, 2015 | $25.05M | +28.0% |
| FY2014 | Dec 31, 2014 | $19.57M | +67.3% |
| FY2013 | Dec 31, 2013 | $11.70M | +24.0% |
| FY2012 | Dec 31, 2012 | $9.44M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $34.31M | +68.6% |
| Q2 FY2026 | Jun 30, 2026 | $19.39M | +60.5% |
| Q1 FY2026 | Mar 31, 2026 | $17.90M | +68.5% |
| Q4 FY2025 | Dec 31, 2025 | $95.03M | +40646.7% |
| Q3 FY2025 | Sep 30, 2025 | $20.35M | +1086.2% |
| Q2 FY2025 | Jun 30, 2025 | $12.08M | +92.2% |
| Q1 FY2025 | Mar 31, 2025 | $10.63M | +76.4% |
| Q4 FY2024 | Dec 31, 2024 | $233.21K | -95.6% |
| Q3 FY2024 | Sep 30, 2024 | $1.72M | -67.6% |
| Q2 FY2024 | Jun 30, 2024 | $6.29M | +54.3% |
| Q1 FY2024 | Mar 31, 2024 | $6.03M | +11.2% |
| Q4 FY2023 | Dec 31, 2023 | $5.29M | -10.2% |
| Q3 FY2023 | Sep 30, 2023 | $5.29M | +7.5% |
| Q2 FY2023 | Jun 30, 2023 | $4.07M | -48.9% |
| Q1 FY2023 | Mar 31, 2023 | $5.42M | -43.6% |
| Q4 FY2022 | Dec 31, 2022 | $5.89M | -54.3% |
| Q3 FY2022 | Sep 30, 2022 | $4.92M | -62.9% |
| Q2 FY2022 | Jun 30, 2022 | $7.97M | -21.6% |
| Q1 FY2022 | Mar 31, 2022 | $9.60M | -13.8% |
| Q4 FY2021 | Dec 31, 2021 | $12.90M | +10.0% |
| Q3 FY2021 | Sep 30, 2021 | $13.28M | +24.5% |
| Q2 FY2021 | Jun 30, 2021 | $10.17M | +3.0% |
| Q1 FY2021 | Mar 31, 2021 | $11.15M | -12.0% |
| Q4 FY2020 | Dec 31, 2020 | $11.72M | +2.2% |
| Q3 FY2020 | Sep 30, 2020 | $10.67M | -0.5% |
| Q2 FY2020 | Jun 30, 2020 | $9.87M | -24.5% |
| Q1 FY2020 | Mar 31, 2020 | $12.67M | +7.6% |
| Q4 FY2019 | Dec 31, 2019 | $11.47M | -4.8% |
| Q3 FY2019 | Sep 30, 2019 | $10.72M | +10.2% |
| Q2 FY2019 | Jun 30, 2019 | $13.07M | +40.5% |
| Q1 FY2019 | Mar 31, 2019 | $11.77M | +26.6% |
| Q4 FY2018 | Dec 31, 2018 | $12.04M | +79.2% |
| Q3 FY2018 | Sep 30, 2018 | $9.73M | +68.3% |
| Q2 FY2018 | Jun 30, 2018 | $9.30M | +62.6% |
| Q1 FY2018 | Mar 31, 2018 | $9.30M | +58.2% |
| Q4 FY2017 | Dec 31, 2017 | $6.72M | +10.9% |
| Q3 FY2017 | Sep 30, 2017 | $5.78M | – |
| Q2 FY2017 | Jun 30, 2017 | $5.72M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.88M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.06M | – |
See a number that looks wrong?